Woo-Sung Yun, Shin-Seok Yang
This study aimed to evaluate peripherally inserted central catheters (PICCs) and totally implanted venous access devices (TIVADs) as chemotherapy delivery routes. From May 2016 to April 2019, patients with malignancies who had PICCs or TIVADs inserted for chemotherapy were enrolled. We reviewed the patients' medical records for information concerning demographics, comorbidities, catheter-related complications, and catheter -service days. All patients included in both groups were also assessed for complication-free catheter survival and completion rates of chemotherapy...
April 2021: Science Progress
Christopher W Noel, Rinku Sutradhar, Haoyu Zhao, Victoria Delibasic, David Forner, Jonathan C Irish, John Kim, Zain Husain, Alyson Mahar, Irene Karam, Danny J Enepekides, Kelvin K W Chan, Simron Singh, Julie Hallet, Natalie G Coburn, Antoine Eskander
No abstract text is available yet for this article.
May 5, 2021: Journal of Clinical Oncology
Charles Craddock, Aimee Jackson, Sylvie D Freeman
No abstract text is available yet for this article.
May 5, 2021: Journal of Clinical Oncology
Hannah Collacott, Vikas Soekhai, Caitlin Thomas, Anne Brooks, Ella Brookes, Rachel Lo, Sarah Mulnick, Sebastian Heidenreich
BACKGROUND: As the number and type of cancer treatments available rises and patients live with the consequences of their disease and treatments for longer, understanding preferences for cancer care can help inform decisions about optimal treatment development, access, and care provision. Discrete choice experiments (DCEs) are commonly used as a tool to elicit stakeholder preferences; however, their implementation in oncology may be challenging if burdensome trade-offs (e.g. length of life versus quality of life) are involved and/or target populations are small...
May 5, 2021: Patient
Weijie Ma, Brian Pham, Tianhong Li
Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programed cell death protein 1 (PD-1) or its ligand PD-L1 have increased the survival and cure rates for patients with many cancer types in various disease settings. However, only 10-40% of cancer patients benefited from these ICIs, of whom ~ 20% have treatment interruption or discontinuation due to immune-related adverse events that can be severe and even fatal. Current efforts in precision immunotherapy are focused on improving biomarker-based patient selection for currently available ICIs and exploring rationale combination and novel strategies to expand the benefit of immunotherapy to more cancer patients...
May 5, 2021: Clinical & Experimental Metastasis
Russell S Witte, Ehab A Tamimi
In recent years, there has been a progressive trend towards less invasive technologies for detecting metastatic cancer and guiding therapy with the goal of lower morbidity, better outcomes, and superior cosmetic appearance than traditional methods. This mini-review examines three emerging noninvasive hybrid technologies for detecting primary cancer, metastasis and guiding thermal therapy. Real-time thermoacoustic imaging and thermometry potentially provides valuable and critical feedback for guiding focused microwave ablation therapy...
May 5, 2021: Clinical & Experimental Metastasis
Michael Bernas, Saskia R J Thiadens, Paula Stewart, Jay Granzow
This manuscript is a summary of findings focusing on various aspects of secondary lymphedema specifically as a sequelae of treatment for cancer. The topic was addressed at a session held during the 8th International Congress on Cancer Metastasis that was unique a for the inclusion of patients with lymphedema and therapists joining physicians, healthcare professionals, and researchers in an effort to give an overview of secondary lymphedema following cancer therapy as well as highlighting the unknowns in the field...
May 5, 2021: Clinical & Experimental Metastasis
Aurora S Blucher, Gordon B Mills, Yiu Huen Tsang
Precision treatment for breast cancers has made several notable advances in recent decades, but challenges of tumor heterogeneity, drug resistance, and aggressive recurrence and metastases remain. To meet and overcome these challenges, we must refine our understanding of breast subtypes and treatment biomarkers according to the knowledge afforded across the spectrum of 'omics assays. A critical aspect of harnessing this knowledge into actionable biomarkers for treatment decision relies on our ability to integrate knowledge across data types and leverage our insight in evidence-based clinical trials...
May 5, 2021: Clinical & Experimental Metastasis
Yoshiaki Shoji, Satoru Furuhashi, Daniel F Kelly, Anton J Bilchik, Dave S B Hoon, Matias A Bustos
Brain metastasis (BM) frequently occurs in patients with cutaneous melanoma, lung, and breast cancer; although, BM rarely arises from cancers of the gastrointestinal tract (GIT). The reported incidence of GIT cancer BM is less than 4%. In the last few years, effective systemic therapy has prolonged the survival of GIT patients and consequently, the incidence of developing BM is rising. Therefore, the epidemiology and biology of BM arising from GIT cancer requires a more comprehensive understanding. In spite of the development of new therapeutic agents for patients with metastatic GIT cancers, survival for patients with BM still remains poor, with a median survival after diagnosis of less than 4 months...
May 5, 2021: Clinical & Experimental Metastasis
Rachel Martini, Lisa Newman, Melissa Davis
Breast cancer (BC) remains a leading cause of death among women today, and mortality among African American women in the US remains 40% higher than that of their White counterparts, despite reporting a similar incidence of disease over recent years. Previous meta-analyses and studies of BC mortality highlight that tumor characteristics, rather than socio-economic factors, drive excess mortality among African American women with BC. This is further complicated by the heterogeneity of BC, where BC can more appropriately be defined as a collection of diseases rather than a single disease...
May 5, 2021: Clinical & Experimental Metastasis
S David Nathanson, Michael Detmar, Timothy P Padera, Lucy R Yates, Danny R Welch, Thomas C Beadnell, Adam D Scheid, Emma D Wrenn, Kevin Cheung
Invasive breast cancer tends to metastasize to lymph nodes and systemic sites. The management of metastasis has evolved by focusing on controlling the growth of the disease in the breast/chest wall, and at metastatic sites, initially by surgery alone, then by a combination of surgery with radiation, and later by adding systemic treatments in the form of chemotherapy, hormone manipulation, targeted therapy, immunotherapy and other treatments aimed at inhibiting the proliferation of cancer cells. It would be valuable for us to know how breast cancer metastasizes; such knowledge would likely encourage the development of therapies that focus on mechanisms of metastasis and might even allow us to avoid toxic therapies that are currently used for this disease...
May 5, 2021: Clinical & Experimental Metastasis
Yaseen Hussain, Jing Hao Cui, Haroon Khan, Michael Aschner, Gaber El-Saber Batiha, Philippe Jeandet
Epithelial to mesenchymal transition (EMT) is a physiological process that assumes a primary role in the induction of cancer metastasis. This results in increased cell renewal, and resistance to cell death and therapies. EMT, therefore, represents an effective strategy for regulating cancerous cell activity. A need for efficacy and low cytotoxicity epithelial to mesenchymal transition modifying drugs has led to the investigational testing of the efficacy of plethora of different groups of phytonutrients. Luteolin is a natural flavonoid inhibits the growth of cancer cells by various mechanisms, such as the stimulation of cancer cell apoptosis, cell cycle arrest, inhibition of cell replication, tumor growth, improvement of drug resistance, prevention of cancer cell intrusiveness and metastasis...
May 5, 2021: Medical Oncology
Xin He, Xiaoguang Ma, Congcong Wang, Mingchun Luan, Ying Li, Xiaohua Huang, Keli Ma
No abstract text is available yet for this article.
May 5, 2021: Journal of Cancer Research and Clinical Oncology
Nicole Heerde, Wolf-Karsten Hofmann, Ralf-Dieter Hofheinz, Sylvia Büttner, Deniz Gencer
PURPOSE: Providing state-of-the-art palliative care is crucial in all areas of in- and outpatient settings. Studies on the implementation of palliative care standards for dying patients are rare. METHODS: N = 141 physicians from all internal departments were polled anonymously about the treatment of dying patients using a self-designed questionnaire. Furthermore, we evaluated the terminal care of n = 278 patients who died in internal medicine departments at University Hospital Mannheim between January and June, 2019 based on clinical data of the last 48 h of life...
May 5, 2021: Journal of Cancer Research and Clinical Oncology
Andres M Corona, Long Di, Ashish H Shah, Raphael Crespo, Daniel G Eichberg, Victor M Lu, Evan M Luther, Ricardo J Komotar, Michael E Ivan
INTRODUCTION: Atypical (WHO grade II) and malignant meningiomas (WHO Grade III) are a rare subset of primary intracranial tumors. Given their relatively high recurrence rate after surgical resection and radiotherapy, there has been a recent push to explore other adjuvant treatment options for these treatment-refractory tumors. Recent advances in molecular sequencing of tumors have elucidated new pathways and drug targets which are currently being studied. This article provides a thorough overview of novel investigational therapeutics including targeted therapy, immunotherapy, and new technological modalities for atypical and malignant meningiomas...
May 5, 2021: Journal of Neuro-oncology
David W Lim, Kelly A Metcalfe
No abstract text is available yet for this article.
May 5, 2021: Annals of Surgical Oncology
Hiroshi Doi, Keisuke Tamari, Ryoong-Jin Oh, Carsten Nieder
PURPOSE: To provide additional clinical data about the re-irradiation tolerance of the spinal cord. METHODS: This was a retrospective bi-institutional study of patients re-irradiated to the cervical or thoracic spinal cord with minimum follow-up of 6 months. The maximum dose (Dmax) and dose to 0.1cc (D0.1cc) were determined (magnetic resonance imaging [MRI]-defined cord) and expressed as equivalent dose in 2‑Gy fractions (EQD2) with an α/β value of 2 Gy...
May 5, 2021: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Ali Berkant Avci, Eugen Feist, Gerd Rüdiger Burmester
The first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in RA, it may also carry an increased risk of toxicity. Subsequently, more selective JAK inhibitors were developed with the aim of improving the safety-efficacy profile and to further increase drug maintenance. With this proposal, early phase trials of selective JAK1 inhibitors, namely upadacitinib, filgotinib and itacitinib, were initiated in recent years to identify the efficacy and adverse effects of these agents and to define their potential role in treatment of inflammatory and autoimmune diseases...
May 5, 2021: Rheumatology
Rosilene Aparecida Costa Amaral, Patrícia Peres de Oliveira, Deborah Franscielle da Fonseca, Thalyta Cristina Mansano Schlosser, Juliano Teixeira Moraes, Edilene Aparecida Araújo da Silveira, Kelli Borges Dos Santos
OBJECTIVES: to construct and assess bundle content for the prevention and management of complications in neutropenia in cancer patients. METHODS: a methodological study developed in four stages: scoping review; bundle construction; material assessment by experts (developed according to Pasquali's psychometry); pilot test in a High Complexity Assistance Unit in Oncology. For content assessment, the Delphi technique was applied in two rounds and those items with Content Validation Coefficient (CVC)> 0...
2021: Revista Brasileira de Enfermagem
Eric Y Kok, Lakshmi Srivaths, Amanda B Grimes, Tiphanie P Vogel, S Kristen Sexson Tejtel, Eyal Muscal
Patients with coronavirus disease 2019 (COVID-19) from novel coronavirus (SARS-CoV-2) infection may present with immune thrombocytopenia (ITP). Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 causing systemic organ dysfunction. This case series presents the first reported cases of patients who developed ITP following MIS-C, while completing corticosteroid tapers. These patients responded to standard of care therapies for ITP and had appropriate platelet count recovery...
May 5, 2021: Pediatric Hematology and Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"